阿斯利康：将从纳斯达克退市，预计从2月2日起在纽交所开始交易
Cai Jing Wang·2026-01-20 10:07
Core Viewpoint - AstraZeneca plans to delist its American Depositary Receipts (ADRs) and debt securities from Nasdaq and list them on the New York Stock Exchange (NYSE), effective after market close on January 30, 2026 [1] Group 1 - The transition from Nasdaq to NYSE is a strategic move by AstraZeneca [1] - The announcement was made on January 20 [1]